



PRESS RELEASE, April 27, 2020

SelectImmune Pharma appoints new CEO

Since SelectImmune Pharma's IPO in 2019, a process successfully overseen by Fredrik Herslow, the company's operations have grown. The projects related to immunotherapy against infections are rapidly developing and are now in clinics, altering somewhat the nature of operations. Fredrik Herslow, who has been the company's CEO since the IPO, will now be standing down on May 1 to be replaced by Jakob Testad, who steps in as acting CEO. The Board of Directors has begun work to recruit a new permanent CEO.

Jakob Testad has an educational background in business administration specializing in financing and commercial law at Lund University, and has been active as an economist at Lund University holding several positions since 2007. Over a period of around 15 years, Jakob Testad has also worked with SelectImmune Pharma's fellow Group company Hamlet Pharma AB as well as Linnane Pharma AB. Accordingly, Jakob possesses knowledge of both SelectImmune Pharma and HAMLET Pharma and is highly familiar with the companies' research portfolios, routines and personnel.

"It is sad to have to leave SelectImmune, but at the same time it feels appropriate now that clinical data has emerged that supports the company's projects," says Fredrik Herslow, who remains a shareholder. "Because of the unexpected success of the investments and recruitments that Herslow & Partners made before the turn of the year, I must unfortunately prioritize this business."

For more information, please contact:

Catharina Svanborg

Chairman of the Board, SelectImmune Pharma AB

Tel: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

This information is inside information that SelectImmune AB is required to publish under the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication on April 27, 2020.